TRILYTE w. FLAVOR PACKS Rx
Generic Name and Formulations:
Polyethylene glycol 3350 420g, sodium chloride 11.2g, potassium chloride 1.48g, sodium bicarbonate 5.72g, flavor 3.22g/pack; per 4 liters of soln; pwd for reconstitution (add 1 flavor pack before reconstitution).
Indications for TRILYTE w. FLAVOR PACKS:
Bowel cleansing before colonoscopy.
After fasting for 3–4 hrs, 240mL orally every 10 minutes or 20–30mL/minute by NG tube until rectal discharge is clear or 4 liters consumed. May interrupt if severe GI disturbances occur. Only clear liquids until exam.
<6months: not recommended. ≥6months: No solid food for at least 2 hrs, then 25mL/kg per hour orally or by NG tube until rectal discharge is clear or 4 liters consumed. May interrupt if severe GI disturbances occur. Only clear liquids until exam.
GI obstruction or perforation. Gastric retention. Toxic colitis. Toxic megacolon. Ileus.
Severe ulcerative colitis. Impaired gag reflex. Semi- or unconsciousness. Risk of aspiration or regurgitation. Pregnancy (Cat.C). Monitor young children (<2yrs) for hypoglycemia or dehydration.
Isosmotic bowel cleanser.
Drugs administered within 1 hour of start of TriLyte may not be absorbed.
Nausea, abdominal fullness or bloating, cramps, vomiting, anal irritation. Children: dehydration, hypokalemia.
TriLyte w. Flavor Packs—4L (disposable bottle w. flavor packs attached)
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Comparing Osteoporosis Screening, Treatment Strategies in Postmenopausal Women
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- Cerebral Small Vessel Disease More Common in Individuals With T1D vs General Population
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Risk for Congenital Heart Defects in Offspring of Mothers With Obesity
- Is the MiniMed 670G System Safe for Children With Type 1 Diabetes?
- Gender-Affirming Hormonal Treatment and Long-Term Bone Safety
- Obesity Linked to Lower Gray Matter Brain Volume
- No Evidence for Health Benefits of Nonsugar Sweeteners